Helena A. Yu, MD

Looking Ahead: Unmet Needs and Future Directions in the Treatment of Advanced EGFR-Mutant NSCLC

May 2nd 2025

Panelists discuss how despite recent advances in first-line treatments, unmet needs remain. These include better personalized care, community education, understanding resistance mechanisms, central nervous system (CNS) metastases management, and development of novel therapies such as antibody-drug conjugates.

45-Year-Old Never-Smoker with Advanced EGFR-Mutant NSCLC and CNS Metastases Treated with the MARIPOSA Regimen

May 2nd 2025

Panelists discuss how a 45-year-old anxious patient who refused chemotherapy was successfully treated with amivantamab plus lazertinib along with prophylactic management strategies for potential adverse effects.

56-Year-Old Never-Smoker Female with High-Risk Metastatic EGFR-Mutant NSCLC Treated with the FLAURA2 Regimen

May 2nd 2025

Panelists discuss how a 56-year-old patient with high-risk disease features was successfully treated with osimertinib plus chemotherapy, achieving excellent response before eventually discontinuing pemetrexed maintenance while continuing osimertinib.

Evaluating Pemetrexed Exposure in FLAURA2: Key Findings and Treatment Implications

May 2nd 2025

Panelists discuss how the FLAURA2 pemetrexed exposure subanalysis showed that patients could benefit from the regimen even if they didn't complete the full maintenance period as prescribed in the trial.

FLAURA2 Maintenance: Key Strategies for Treatment Optimization and Patient Monitoring

May 2nd 2025

Panelists discuss how FLAURA2 maintenance therapy strategies involve monitoring patients for toxicities and implementing dose modifications or schedule adjustments to improve tolerability.

Weighing QoL and Toxicity in 1L EGFRm NSCLC Treatment Decisions

May 2nd 2025

Panelists discuss how quality-of-life (QoL) considerations and individual toxicity profiles significantly impact first-line (1L) treatment decisions, with different regimens having distinct adverse effect profiles.

Impact of Disease Characteristics on 1L Treatment Decisions in EGFRm NSCLC

May 2nd 2025

Panelists discuss how disease characteristics such as central nervous system (CNS) metastases can influence treatment decisions, with both FLAURA2 and MARIPOSA trials showing superior outcomes for patients with brain metastases when using combination therapies.

Balancing Clinical and Patient-Centered Factors in 1L EGFRm NSCLC Treatment

May 2nd 2025

Panelists discuss how patient-centered factors are crucial in shared decision-making for first-line (1L) treatment, with a potential default approach of offering combination therapy with an option to choose osimertinib monotherapy.

Translating OS Data Into Patient Conversations: Balancing Benefit and Burden

May 2nd 2025

Panelists discuss how explaining survival benefits to patients must be tailored to individual goals and expectations, with many patients having specific life milestones they hope to reach.

Balancing Survival and Quality of Life in 1L EGFRm NSCLC Treatment Decisions

May 2nd 2025

Panelists discuss how treatment choice involves weighing quality of life against treatment burden, considering factors such as hospital visits for infusions vs oral medications at home.

Understanding OS Through 2 Lenses: Patients and Providers in EGFRm NSCLC

May 2nd 2025

Panelists discuss how health care providers and patients view survival differently, with providers being more data driven and patients focusing on living with minimal symptoms and maintaining quality of life.

Overall Survival as a Driver of 1L EGFRm NSCLC Treatment Selection

May 2nd 2025

Panelists discuss how overall survival is an important but not the only consideration in treatment decision-making, with factors such as patient characteristics, disease burden, and quality of life also being critical.

MARIPOSA OS Data: Shaping Frontline Treatment in EGFR-Mutant NSCLC

April 25th 2025

Panelists discusses how the MARIPOSA trial demonstrated significant survival improvement with amivantamab plus lazertinib versus osimertinib alone in EGFR-mutant NSCLC, showing a hazard ratio of 0.75 and an expected 12-month survival benefit that could potentially change the natural history of this disease.

EGFR-Mutant NSCLC: Navigating an Increasingly Complex Treatment Landscape

April 25th 2025

Panelists discuss the increasing complexity in treatment decision-making for EGFR-mutant non–small cell lung cancer (NSCLC) with multiple frontline options now available.

Patient Selection and Sequencing of NSCLC ADCs

August 19th 2024

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Mitigating Toxicities of Dato-DXd, Sacituzumab Govitecan, and HER3-DXd

August 12th 2024

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

Key ADC Studies at ASCO 2024

August 12th 2024

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

Challenges and Learnings from EVOKE-01

August 5th 2024

Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.

Targeting of HER3: Insights from HERTHENA-Lung01

August 5th 2024

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.

Key Takeaways from TROPION Trials: Implications for NSCLC Treatment Landscape

July 29th 2024